anifrolumab Archives

Tag: anifrolumab

Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments

November 14, 2019 The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly encouraged by the positive results reported for several potential new treatments that may help people with lupus. “The foundational work the Lupus Research Alliance and others have supported is beginning to bear fruit with potential […] Read More

Lupus Research Alliance Response to Positive Data from Phase 3 Anifrolumab Trial Presented at 2019 ACR/ARP Annual Meeting

NEW YORK, NY – November 11. The Lupus Research Alliance (LRA) congratulates AstraZeneca on new positive results from the Phase 3 TULIP-2 trial (Treatment of Uncontrolled Lupus via the Interferon Pathway) presented at the 2019 ACR/ARP Annual Meeting. The data showed that the investigational biologic treatment anifrolumab significantly reduced disease activity for people with lupus. […] Read More

LRA Applauds Exciting Lupus Research Being Presented at 2019 ACR/ARP Annual Meeting

Includes 16 presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from two clinical studies conducted by LRA-affiliate Lupus Therapeutics (LT) in collaboration with Rilite Foundation and Pfizer to be presented Extensive positive studies focused on lupus, including successful Phase 3 and Phase 2 clinical and mechanistic data […] Read More

MOMENTOUS NEWS — Potential New Lupus Treatment Effectively Reduced Disease Activity in Phase III Trial

NEW YORK, NY. August 29 — The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. Over 15 studies […] Read More

ACR|ARHP News on Potential New Lupus Treatments

October 25, 2018 The Lupus Research Alliance was on the ground at the American College of Rheumatology 2018 meeting to bring you the latest news in lupus research and translation. Several clinical trials showed benefits of potential new treatments for helping people with lupus. Following are summaries of the stand-out results: Ustekinumab (Stelara®) A Phase 2 […] Read More